News & analysis on the clinical development and manufacture of large molecule drugs
By Natalie Morrison
- Last updated on
The company says his expertise will enable it to provide additional contract research services to pharmaceutical and biotech companies developing large molecule drugs and other biologics.
In addition to leading the expansion of MicroConstants’ immunology department, Lilin will serve as a principal investigator and direct the development and validation of ELISA immunoassays, enzymatic activity assays, and immunogenicity testing for pharmaceuticals, biomarkers, and antibodies.
David Beyerlein, vice president of global operations at MicroConstants, said: “Our immunology department was established in 2007 to provide immunoassay and biomarker analysis services to clients developing proteins and peptides.
“Lilin’s experience will allow us to expand those services to also include cell-based and molecular assay development which can provide insight into drug metabolism and drug target interactions in vivo.”